Social Media Ideas for Crystalys Therapeutics

Crystalys nets $130M more to push gout drug through late-stage tests

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t y...

Crystalys mines $130M series B to push gout drug through phase 3

Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.

Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug

Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecul...

An eye drug biotech banks $118M and stocks its executive suite

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell defic...

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve...

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in pr...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

<![CDATA[Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement ]]>

Calliditas?

Calliditas? Anonymous (not verified) Wed, 08/12/2026 - 00:32 field_thread_url https://cafepharma.com/boards/threads/calliditas.661472/ b...

Calliditas?

Calliditas? Anonymous (not verified) Tue, 08/18/2026 - 03:36 field_thread_url https://cafepharma.com/boards/threads/calliditas.661472/ b...

Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill

Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Sat, 09/05/2026 - 12:48 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

<![CDATA[Aptar and Aceso Therapeutics Enter Collaboration for Cystic Fibrosis Therapy ]]>

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Pro...

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics]]>

AbCellera, Vertex partner on next-gen T-cell engagers

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medi...

‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug

A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.

Karyopharm - oncology

Karyopharm - oncology Anonymous (not verified) Mon, 08/10/2026 - 00:31 field_thread_url https://cafepharma.com/boards/threads/karyopharm-oncology.624681/...

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Wed, 07/29/2026 - 18:25 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>

Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug

Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.